GLP-1 Medications vs Bariatric Surgery: Which is Right for Long-Term Weight Loss?
GLP-1 Medications vs Bariatric Surgery: Which is Right for Long-Term Weight Loss?
By Dr. Jason Maani | Medically reviewed July 2026
Two of the most significant advances in weight management in the past decade are GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro) and bariatric surgery (gastric sleeve, gastric bypass). Both produce real results. Both have limitations. And for many Australians, the question is which one is right for them.
This guide compares GLP-1 medications and bariatric surgery head-to-head across the metrics that matter: weight loss magnitude, durability, metabolic outcomes, cost, risk, and lifestyle impact.
The Short Answer
- GLP-1 medications produce 12–22% body weight loss — significant and meaningful, but typically less than surgery
- Bariatric surgery produces 60–80% excess weight loss (equivalent to 20–35%+ of total body weight) — currently the most effective long-term intervention available
- The right choice depends on your BMI, medical history, budget, and preference for a reversible vs permanent solution
- For many patients, both may be appropriate at different stages of their journey
Weight Loss: How Do They Compare?
GLP-1 Medications
| Medication | Average Weight Loss | Duration of Trial |
|---|---|---|
| Ozempic (semaglutide 2mg) | 12–15% body weight | 68 weeks |
| Wegovy (semaglutide 2.4mg) | 15–17% body weight | 68 weeks |
| Mounjaro (tirzepatide 15mg) | 20–22% body weight | 72 weeks |
These are averages. Individual results vary considerably — some patients lose more, some less. The results are maintained only while the medication is being taken.
What happens when you stop? Most patients regain a significant portion of lost weight within 12 months of stopping GLP-1 medication. The STEP 4 trial showed participants regained approximately two-thirds of lost weight within a year of stopping Wegovy. This is a biological response, not a failure.
Bariatric Surgery
| Procedure | Excess Weight Loss (5 years) | Total Body Weight Loss |
|---|---|---|
| Gastric Sleeve | 50–65% EWL | Approx. 20–30% |
| Gastric Bypass | 65–80% EWL | Approx. 25–35% |
For someone 50kg above their healthy weight range, gastric bypass could mean losing 32–40kg and maintaining most of that loss at 5 years. Surgery also produces hormonal changes — particularly in GLP-1 itself — that help regulate appetite post-operatively.
What happens long-term? The SOS (Swedish Obese Subjects) study followed bariatric patients for 20 years. At 20 years, bariatric patients had significantly lower rates of diabetes, cardiovascular events, and cancer mortality compared to non-surgical controls.
Metabolic Outcomes: Beyond the Scale
Both approaches improve weight-related health conditions, but surgery generally produces more dramatic results.
| Outcome | GLP-1 Medications | Bariatric Surgery |
|---|---|---|
| Type 2 diabetes remission | 10–20% achieve remission | 60–70% achieve remission |
| Blood pressure improvement | Moderate | Significant |
| Sleep apnoea resolution | Partial | Often complete resolution |
| Cholesterol improvement | Moderate | Significant |
| Cardiovascular risk | Reduced (SELECT trial: 20% risk reduction with Wegovy) | Reduced (lower long-term mortality) |
| GORD (reflux) | Generally neutral | May worsen with sleeve; improves with bypass |
The cardiovascular evidence for GLP-1 medications is growing rapidly. The SELECT trial showed semaglutide (Wegovy dose) reduced major cardiovascular events by 20% in patients with overweight/obesity and existing cardiovascular disease — without significant weight loss being required for the benefit.
Cost Comparison (Australia, 2026)
GLP-1 Medications
| Medication | Monthly Cost (Private) | Annual Cost |
|---|---|---|
| Ozempic (diabetes PBS) | $32–44 | $384–528 |
| Ozempic (off-label) | $200–350 | $2,400–4,200 |
| Wegovy | $350–500 | $4,200–6,000 |
| Mounjaro | $350–600 | $4,200–7,200 |
Costs are ongoing for as long as the medication is taken — which for most people is indefinitely.
Bariatric Surgery
| Scenario | Approximate Cost |
|---|---|
| Private health insurance (with appropriate cover) | $3,000–8,000 out-of-pocket |
| Self-funded (no insurance) | $12,000–20,000 |
| Public system | Free (long waiting list, strict criteria) |
Surgery is a one-time cost (plus supplements and follow-up). At Wegovy pricing, surgery pays for itself within 3–5 years.
Risk Profile
GLP-1 Medications
Common:
- Nausea (especially during dose escalation — usually resolves)
- Vomiting, diarrhoea, constipation
- Fatigue
Uncommon/serious:
- Pancreatitis (rare)
- Gallbladder disease (increased risk)
- Thyroid concerns (based on animal data; unclear in humans)
Key risk: Side effects are manageable for most people, but approximately 10–15% of patients discontinue due to gastrointestinal intolerance.
Bariatric Surgery
Short-term:
- Staple line leak or bleed (1–2%)
- DVT/pulmonary embolism (standard prophylaxis used)
- Anaesthetic risk
Long-term:
- Nutrient deficiencies (iron, B12, D, calcium — lifelong supplementation required)
- GORD worsening (sleeve) or improvement (bypass)
- Some weight regain after 2–3 years (usually manageable)
Overall mortality risk: Approximately 0.1% in accredited Australian bariatric centres — comparable to routine gallbladder surgery.
Reversibility
GLP-1 medications: Fully reversible. You stop the injection and the drug’s effects reverse within days to weeks. Weight returns over months.
Bariatric surgery: Permanent. The removed portion of the stomach cannot be restored. Revision procedures are possible but carry higher risk than primary surgery. This permanence is both a strength (you can’t “undo” it impulsively) and a consideration for younger patients.
Who Should Choose GLP-1 Medications?
GLP-1 medication is likely the better starting point if:
- You want to try a reversible option before committing to surgery
- Your BMI is under 35, making you ineligible for most surgical programmes
- You have Type 2 diabetes and want PBS-supported access (Ozempic)
- You have significant cardiovascular risk and want the proven SELECT trial benefits
- You have concerns about surgical risk or anaesthesia
- Your weight loss target is 10–20% and you are comfortable with ongoing monthly costs
Who Should Consider Bariatric Surgery?
Surgery is likely the stronger option if:
- Your BMI is ≥40, or ≥35 with significant comorbidities
- You’ve tried GLP-1 medications without achieving adequate results
- You want a one-time intervention rather than lifelong medication
- The 20-year outcome data matters to you — surgery has it, medications don’t yet
- You have severe Type 2 diabetes where remission is the goal
- Cost over time is a factor — surgery is cost-effective within 5–10 years vs ongoing medication
Can You Do Both?
Yes — and this is increasingly common in clinical practice. GLP-1 medications are sometimes used:
- Before surgery to reduce liver size and improve surgical conditions
- After surgery to manage weight regain in the years following the procedure
- Instead of revision surgery when post-surgical weight regain occurs
Some patients start with GLP-1 medications and progress to surgery when results plateau or as their BMI reaches surgical eligibility. The two approaches are not mutually exclusive.
Frequently Asked Questions
Q: Is Ozempic better than gastric sleeve for weight loss? A: No — bariatric surgery (including gastric sleeve) produces significantly greater weight loss than Ozempic. Gastric sleeve typically achieves 60–70% excess weight loss at 5 years; Ozempic achieves 12–15% total body weight loss. However, surgery is not appropriate for everyone, and Ozempic is a valid option for those who don’t meet surgical criteria or prefer non-surgical approaches.
Q: Can I switch from Ozempic to bariatric surgery? A: Yes. Many patients begin with GLP-1 medications and later transition to bariatric surgery when results plateau or when their circumstances change. Most surgeons ask you to stop GLP-1 medication several weeks before surgery.
Q: Which has fewer long-term side effects — GLP-1 medication or surgery? A: Both have manageable side effect profiles when properly managed. Surgery requires lifelong nutritional supplementation and has risks of GORD and nutrient deficiency. GLP-1 medications have mainly gastrointestinal side effects during dose escalation, with rare serious risks. Long-term safety data beyond 5 years is stronger for surgery; the GLP-1 evidence base is growing rapidly.
Q: Will I regain weight after stopping GLP-1 medication? A: Yes, most people regain a significant portion of lost weight after stopping GLP-1 medications. Clinical trials show approximately two-thirds of weight returns within 12 months. This is why these medications are generally intended as long-term or indefinite treatment, not a short course.
Q: Is weight loss surgery safer than long-term medication? A: These are different risk profiles and difficult to compare directly. Surgery has a defined, one-time risk (0.1% mortality, 1–2% serious complications). Long-term medication has lower per-dose risk but accumulates over years. For most patients, both are acceptably safe when managed by experienced practitioners.
The Bottom Line
If maximum weight loss and long-term metabolic health outcomes are your goals, bariatric surgery has the strongest evidence. If you prefer a reversible, non-surgical option and have a moderate amount of weight to lose, GLP-1 medications are the most effective non-surgical tool available.
Many Australians benefit from medical consultation that considers both options honestly — not just one or the other. Read our weight loss options overview or explore our deep-dives on gastric sleeve surgery and GLP-1 medications to learn more.
Dr. Jason Maani is the founder of The 99 Percent. This guide is for educational purposes only. Always consult your doctor or a bariatric specialist before making decisions about weight loss treatment.